HALO as reported
Halozyme Therapeutics, Inc. reported $1.51B of revenue over the trailing twelve months, +39% on the year before. 11 reported series are charted on this page, each one as filed.
$1.51B
Revenue, trailing twelve months · to Q1 2026 · +39% against the twelve months before
- Net Income
- $349M
Net Income · −28% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $668M
Free Cash Flow · +35% year on year · trailing twelve months to Q1 2026
- Op Margin
- 38%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $1.51B | +39% | Q1 2026 |
| Net Income | $349M | −28% | Q1 2026 |
| EPS | $2.86 | −24% | Q1 2026 |
| Gross Margin | 83% | n/a | Q1 2026 |
| Op Margin | 38% | n/a | Q1 2026 |
| Net Margin | 27% | n/a | Q1 2026 |
| ROE | 273% | n/a | Q1 2026 |
| ROA | 20% | n/a | Q1 2026 |
| ROIC | 26% | n/a | Q1 2026 |
| Free Cash Flow | $668M | +35% | Q1 2026 |
| P/E | 37.4 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Halozyme Therapeutics, Inc. (HALO) - Revenue & ProfitRevenue & ProfitHalozyme Therapeutics, Inc. (HALO)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com